Showing results (51-60 of 156) with videos related to
Sort By:
Pageof 16
Haematologica|April 22, 2006
Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's diseasePilar Giraldo, Paz Latre, Pilar Alfonso, et al.Blood Cells, Molecules & Diseases|November 15, 2016
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imigluceraseAri Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|August 4, 2020
Serum protein profile analysis in lysosomal storage disorders patientsLaura López de Frutos, Elena García-González, Beatriz García-Rodríguez, et al.Journal of Orthopaedic Surgery and Research|November 23, 2019
Muscle-tendon weakness contributes to chronic fatigue syndrome in Gaucher's diseaseMercedes Roca-Espiau, Marcio Andrade-Campos, Jorge J Cebolla, et al.Haematologica|July 18, 2009
Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL projectPilar Giraldo, Pilar Alfonso, Koldo Atutxa, et al.European Journal of Haematology|May 10, 2016
Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetanMarcio Miguel Andrade-Campos, Paola Liévano, Natalia Espinosa-Lara, et al.The Journal of Clinical Endocrinology and Metabolism|February 20, 2015
Association of ferritin elevation and metabolic syndrome in males. Results from the Aragon Workers' Health Study (AWHS)Marta Ledesma, Yamilee Hurtado-Roca, Montserrat Leon, et al.Medicina Clinica|August 2, 2024
Identification of patient-reported outcomes measures (PROMs) and patient-reported experiences measures (PREMs) in Gaucher disease in SpainPilar Giraldo, María Camprodón, Paloma Cerro Alcolea, et al.American Journal of Hematology|April 23, 2016
Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Suma P Shankar, Milan Petakov, et al.Medicina Clinica|July 9, 2013
[National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Espan˜ola de Hematologı´a y Hemoterapia and Grupo Espan˜ol de Leucemia Linfocı´tica Cro´ nica]José A García Marco, Pilar Giraldo Castellano, Javier López Jiménez, et al.Pageof 16